BioCardia Reports 2019 First Quarter Financial Results and Business Highlights
BioCardia, Inc. (BCDA)
US:NASDAQ Investor Relations:
biocardia.com/investors/press-releases/id/1037?pressreleaseid=41
Company Research
Source: GlobeNewswire
SAN CARLOS, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the first quarter of 2019 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2019 with the Securities and Exchange Commission on May 15, 2019. 2019 Business Highlights: Our lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow-derived cell therapy (using a patient’s own cells) for the treatment of two clinical indications: heart failure that develops after a heart attack, and chronic myocardial ischemia. The Phase III pivotal CardiAMP™ Heart Failure Trial is currently enrolling at 21 world class centers in the United States, with 37 patients enrolled to date. The Phase III pivotal CardiAMP™ Chronic Myocardial Ischemia Trial has been designed t
Show less
Read more
Impact Snapshot
Event Time:
BCDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCDA alerts
High impacting BioCardia, Inc. news events
Weekly update
A roundup of the hottest topics
BCDA
News
- BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... [Yahoo! Finance]Yahoo! Finance
- BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results [Yahoo! Finance]Yahoo! Finance
- BioCardia Reports Third Quarter 2024 Business Highlights and Financial ResultsGlobeNewswire
BCDA
Earnings
- 8/13/24 - Miss
BCDA
Sec Filings
- 11/19/24 - Form 4
- 11/13/24 - Form 8-K
- 11/13/24 - Form 10-Q
- BCDA's page on the SEC website